Sign inJoin waitlistJoin the waitlist

SS

Shalabh Singhal

Cardiovascular Disease

Credentials: · · ·

History

Cardiovascular Disease
Internal Medicine

Research

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Arthritis & Rheumatology · 2023 · Last of 13 authors · 209 citations
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Annals of the Rheumatic Diseases · 2022 · 175 citations
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy
Pharmacotherapy · 2007 · 80 citations

SB
Subhashis Banerjee
5 papers
CH
Coburn Hobar
3 papers
Ihab Girgis
3 papers
JM
Joan Merrill
2 papers
MP
Marilyn Pike
2 papers
ND
Nikolay Delev
2 papers
Victoria Werth
2 papers
Yukitaka Shizukuda
2 papers
Aferdita Spahillari
1 paper
AK
Alan Kivitz
1 paper
Anca Askanase
1 paper
AG
Arnold Greenspon
1 paper